Integrated DNA Technologies’ rhAmp SNP Genotyping System enables highly precise interrogation of SNPs within difficult genomic regions. For the first time, the IDT rhAmp assay performance was demonstrated on a digital PCR platform — quantifying EGFR p.T790M mutation down to 0.1%.
Application Notes: Oncology
95% of Chronic Myeloid Leukemia (CML) cases are characterized by the presence of a BCR-ABL1 fusion gene. Regular monitoring involving precise quantification of BCR-ABL1 transcripts is integral to successful tyrosine kinase inhibitor (TKI) treatment. Read more about how samples with precise ratios of BCR-ABL1/ABL1 were created and confirmed on the Combinati dPCR platform.
Digital PCR (dPCR) enables rare target detection even in the presence of high non-target background. Read more about how the Applied Biosystems™ TaqMan™ Liquid Biopsy dPCR Assays were used to perform rare target detection for 5 hot-spot cancer mutations on the Combinati Absolute Q platform.